Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2012; 107(01): 4-5
DOI: 10.1160/TH11-11-0790
DOI: 10.1160/TH11-11-0790
Invited Editorial Focus
Mild renal disease increases major bleeding in patients with atrial fibrillation undergoing percutaneous coronary stenting
…or why clinical cardiologists and interventionalists should be friendsFurther Information
Publication History
Received:
08 November 2011
Accepted:
14 November 2011
Publication Date:
20 November 2017 (online)
-
References
- 1 Manzano-Fernández S, Cambronero F, Caro-Martínez C. et al. Mild Kidney Disease is a Risk Factor for Major Bleeding in Patients with Atrial Fibrillation Undergoing Percutaneous coronary stenting. Thromb Haemost 2012; 107: 51-58.
- 2 Manoukian S, Feit F, Mehran R. et al. Impact of major bleeding on 30-Day mortality and clinical outcomes in patients with acute coronary syndromes: analysis from the ACUITY trial. JACC 2007; 49: 1362-1368.
- 3 De Caterina R, Connolly S, Chrolavicius S. et al. on behalf of the ACTIVE Investigators. Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. Eur Heart J 2010; 31: 2133-2140.
- 4 Marinigh R, Lane DA, Lip GY.. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 2011; 57: 1339-1348.
- 5 Lip GY, Andreotti F, Fauchier L. et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011; 106: 997-1011.
- 6 To AC, Yehia M, Collins JF.. Atrial fibrillation in Haemodialysis patients: do the guidelines for anticoagulation apply?. Nephrology 2007; 12: 441-447.
- 7 Fang MC, Go AS, Chang Y. et al. A new risk scheme to predict warfarin-associated hemorrhage. JACC 2011; 58: 395-401.
- 8 Lip GY, Huber K, Anderotti F. et al. European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost 2010; 103: 13-28. [Erratum in Thromb Haemost 2010; 104: 653.]
- 9 Huber K, Airaksinen KJ, Cuisset T. et al. Antithrombotic therapy in patient with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost 2011; 106: 569-579.
- 10 Faxon DP, Eikelboom JW, Berger PB. et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011; 106: 572-584.
- 11 Alexander J, Lopes R, James S. et al. for the APPRAISE-2 Investigators. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. N Engl J Med 2011; 365: 699-708.